title: Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support.
abstract: Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) produces dose-related therapeutic and toxic effects; however, relationships between its pharmacokinetics and pharmacodynamics have not been extensively evaluated. The following studies were undertaken to investigate patterns in the disposition of rHuGM-CSF administered after high-dose chemotherapy (cyclophosphamide, cisplatin, carmustine) and autologous bone marrow support. Continuous 14 or 21 day intravenous infusions or daily 4-hour infusions were studied at doses of 1.2 to 19.2 micrograms/kg/d. GM-CSF was measured by an enzyme-linked immunosorbent assay from serum and urine samples collected throughout drug administration. Pharmacokinetic parameters were determined by compartmental (4-hour infusions) or noncompartmental methods (continuous infusions). GM-CSF was rapidly eliminated from the serum. Average systemic exposure increased with dose, although wide interpatient variability was evident. Approximately one half of the patients receiving continuous infusions demonstrated increasing GM-CSF clearance that corresponded to the appearance of white blood cells in the periphery. Conversely, clearance decreased in those experiencing renal dysfunction during the infusion. The percentage of a GM-CSF dose found in 24-hour urine collections was substantially reduced in the latter group. A subset of patients who developed renal dysfunction also experienced significant hypotension. Rapidly increasing serum GM-CSF concentrations corresponded to the hypotensive episodes. GM-CSF serum concentration monitoring may be useful for evaluation of therapeutic and toxic effects in patients receiving high-dose chemotherapy with autologous bone marrow support.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC 27710.
authors.forename: W P
authors.initials: WP
authors.lastname: Petros
authors.forename: J
authors.initials: J
authors.lastname: Rabinowitz
authors.forename: A R
authors.initials: AR
authors.lastname: Stuart
authors.forename: C J
authors.initials: CJ
authors.lastname: Gilbert
authors.forename: Y
authors.initials: Y
authors.lastname: Kanakura
authors.forename: J D
authors.initials: JD
authors.lastname: Griffin
authors.forename: W P
authors.initials: WP
authors.lastname: Peters
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000378:metabolism / Q000628:therapy; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000493:pharmacokinetics*; D006801:Humans; D008545:Melanoma / Q000378:metabolism / Q000628:therapy; D008657:Metabolic Clearance Rate; D011994:Recombinant Proteins / Q000493:pharmacokinetics; D014182:Transplantation, Autologous
chemical_list: D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor